GlassScriptPhysician profile
Richard D Brand
NPI 1770527608
$1,253.77
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $630 · 2020: $331 · 2021: $293.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $279.48 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $148.01 | 2019-2020 | |
| Novo Nordisk INC | $142.60 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.95 | 2019-2021 | |
| Dexcom, INC. | $76.24 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $74.29 | 2019-2020 | |
| Medtronic Minimed, INC. | $69.90 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $66.71 | 2019-2020 | |
| Tandem Diabetes Care, INC. | $59.64 | 2019-2021 | |
| Companion Medical, INC. | $58.28 | 2019-2020 | |
| Abbott Laboratories | $46.13 | 2019-2021 | |
| Insulet Corporation | $44.88 | 2019 | |
| Mannkind Corporation | $39.33 | 2019-2020 | |
| Lilly USA, LLC | $18.03 | 2020 | |
| Vertiflex, INC. | $15.49 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $14.81 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Brand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.